CHRS, US19249H1032

Coherus schedules October 28 webcast for Coherus Oncology stock

Published on 10/20/2026 at 21:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Tagmokitug data webcast is scheduled for October 28, 2026. Coherus Oncology stock costs EUR 0.89 on October 20, 2026 at Lang & Schwarz.

Reporting date October 28, 2026

Coherus Oncology scheduled a Tagmokitug data webcast for October 28, 2026.
Second-quarter 2026 revenue reached USD 14.31 million, up 39.61 percent year over year.
Coherus Oncology stock costs EUR 0.89 at Lang & Schwarz on October 20, 2026 at 9:29 p.m. CEST.

CHRS, US19249H1032, Illustration mit AI erstellt.

Coherus Oncology (ISIN US19249H1032) scheduled a webcast for October 28, 2026 to disclose interim Tagmokitug clinical data, according to Coherus Oncology. The company will discuss its cytolytic CCR8 antibody program with management and outside clinical experts. Coherus Oncology stock was trading at EUR 0.89 at Lang & Schwarz on October 20, 2026 at 9:29 p.m. CEST.

October 28 brings clinical data

The webcast is scheduled from 4:30 p.m. to 6:00 p.m. EDT on October 28, 2026. The program evaluates Tagmokitug with toripalimab in patients with multiple solid tumors, including head and neck, colorectal and gastric cancers, as MarketScreener reported on October 14, 2026.

Coherus describes Tagmokitug as a selective anti-CCR8 antibody in Phase 1b/2a studies. The company is developing it alongside LOQTORZI, its approved programmed death receptor-1 inhibitor, while Casdozokitug remains in a Phase 2 study.

Revenue improved in the second quarter

Coherus reported USD 14.31 million of revenue in the second quarter of 2026, up 39.61 percent from USD 10.25 million in the second quarter of 2025. The company also reported a GAAP net loss of USD 20.63 million, compared with USD 41.34 million a year earlier, according to The Globe and Mail on September 22, 2026.

Nasdaq position and valuation

On Nasdaq, CHRS was last at USD 1.00 on October 20, 2026 at 3:31 p.m. EDT, with 849,132 shares traded. Its USD 0.94 to USD 2.62 52-week range places the latest Nasdaq price USD 0.06 above the low and USD 1.62 below the high.

Coherus had a market capitalization of USD 155.3 million on October 20, 2026. Its trailing P/E ratio was negative 0.99, while the company reported a negative operating result of USD 32.33 million in the second quarter of 2026.

Comparison with peers

Coherus Oncology: P/E negative 0.99, market capitalization USD 155.3 million. Gilead Sciences (Nasdaq, USD): P/E negative 58.35, market capitalization USD 193.5 billion. Amgen (Nasdaq, USD): P/E 27.06, market capitalization USD 235.7 billion.

What comes next

The October 28 webcast is the next dated company event and may provide investors with clinical detail beyond the program description. The scheduled data release also gives the stock a defined event date after the second-quarter revenue increase.

Stock price in euros

Coherus Oncology stock was trading at EUR 0.89 at Lang & Schwarz on October 20, 2026 at 9:29 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Coherus Oncology stock.